Hall Private Wealth Advisors Gilead Sciences, Inc. Transaction History

Hall Private Wealth Advisors

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 14, 2023	SELL	$76.01 - $86.7 $8.28 Million - $9.44 Million	-108,908 Reduced 96.16%	4,352 $335,000
Q1 2023 Apr 18, 2023	SELL	$77.31 - $88.08 $1.15 Million - $1.31 Million	-14,824 Reduced 11.57%	113,260 $9.4 Million
Q4 2022 Jan 20, 2023	SELL	$62.32 - $89.47 $1.37 Million - $1.97 Million	-22,019 Reduced 14.67%	128,084 $0
Q3 2022 Oct 31, 2022	SELL	$59.54 - $68.01 $598,793 - $683,976	-10,057 Reduced 6.28%	150,103 $9.26 Million
Q2 2022 Jul 20, 2022	BUY	$57.72 - $65.01 $923,404 - $1.04 Million	15,998 Added 11.1%	160,160 $9.9 Million
Q1 2022 May 02, 2022	BUY	$57.92 - $72.58 $966,337 - $1.21 Million	16,684 Added 13.09%	144,162 $8.57 Million
Q4 2021 Jan 28, 2022	BUY	$64.88 - $73.64 $804,706 - $913,356	12,403 Added 10.78%	127,478 $9.26 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $4.03 Million - $4.35 Million	59,520 Added 107.14%	115,075 $8.04 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $2.24 Million - $2.45 Million	35,356 Added 175.04%	55,555 $3.83 Million
Q4 2020 Mar 11, 2021	BUY	$56.65 - $64.55 $1.14 Million - $1.3 Million	20,199 New	20,199 $1.18 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Hall Private Wealth Advisors, based on Form 13F filings with the SEC.

Stay updated on Hall Private Wealth Advisors with notifications on news.